Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

Phase 2

Recruiting

Conditions: Primary Immune Deficiency Disorder
Immune Deficiency Disease
Bone Marrow Failure

Interventions: Drug: Alemtuzumab
Drug: Fludarabine
Drug: Melphalan
Radiation: Low Dose Total Body Irradiation
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2020-01-18

Last Posted Date: 2024-12-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 27

Registration Number: NCT04232085

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Biological: CART-PSMA-TGFβRDN
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Anakinra

First Posted Date: 2020-01-13

Last Posted Date: 2023-08-21

Lead Sponsor: Tceleron Therapeutics, Inc.

Target Recruit Count: 16

Registration Number: NCT04227275

Locations: 🇺🇸
The University of Kansas Hospital, Kansas City, Kansas, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 6 locations

Stem Cell Transplantation in Crohn's Disease

Phase 1

Recruiting

Conditions: Crohn Disease

Interventions: Drug: Mesna
Drug: Cyclophosphamide
Drug: Filgrastim
Procedure: Apheresis catheter placement
Procedure: Leukapheresis
Drug: Fludarabine
Drug: Methylprednisolone
Drug: Diphenhydramine
Drug: Acetaminophen
Drug: anti-thymocyte globulin (rabbit)
Drug: lymphocyte immune globulin
Biological: Peripheral Blood Stem Cell Infusion
Drug: Cytoxan

First Posted Date: 2020-01-13

Last Posted Date: 2024-04-10

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 15

Registration Number: NCT04224558

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Phase 1

Recruiting

Conditions: Nodal Marginal Zone Lymphoma
Indolent Non-hodgkin Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Splenic Marginal Zone Lymphoma

Interventions: Drug: CAR.k.28
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine

First Posted Date: 2020-01-10

Last Posted Date: 2024-10-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 20

Registration Number: NCT04223765

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

Phase 1

Recruiting

Conditions: Allogeneic Stem Cell Transplant Recipient
Recurrent Acute Myeloid Leukemia
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Refractory Acute Myeloid Leukemia

Interventions: Drug: Cytarabine Hydrochloride
Biological: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Drug: Fludarabine

First Posted Date: 2020-01-07

Last Posted Date: 2024-05-16

Lead Sponsor: Sumithira Vasu

Target Recruit Count: 21

Registration Number: NCT04220684

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukaemia
High-risk Myelodysplastic Syndrome

Interventions: Drug: Fludarabine
Drug: Cytarabine
Drug: Vyxeos
Drug: Busulphan
Drug: Thiotepa

First Posted Date: 2020-01-03

Last Posted Date: 2023-05-10

Lead Sponsor: University of Birmingham

Target Recruit Count: 333

Registration Number: NCT04217278

Locations: 🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧
Nottingham City Hospital, Nottingham, United Kingdom
🇬🇧
Manchester Royal Infirmary, Manchester, United Kingdom

and more 11 locations

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: B-cell Lymphoma Refractory
B-Cell Acute Lymphoblastic Leukemia, Adult
B-cell Lymphoma Recurrent

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CD19-CD34 CAR transduced T cells

First Posted Date: 2020-01-02

Last Posted Date: 2022-08-15

Lead Sponsor: Loyola University

Target Recruit Count: 24

Registration Number: NCT04214886

Locations: 🇺🇸
Loyola University, Maywood, Illinois, United States

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma
Progressive Disease
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma

Interventions: Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate

First Posted Date: 2019-12-20

Last Posted Date: 2024-12-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT04205838

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

Phase 2

Terminated

Conditions: Recurrent Plasma Cell Myeloma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Daratumumab
Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus

First Posted Date: 2019-12-19

Last Posted Date: 2023-09-28

Lead Sponsor: Srinivas Devarakonda

Target Recruit Count: 1

Registration Number: NCT04205240

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: bb2121
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Lenalidomide

First Posted Date: 2019-12-12

Last Posted Date: 2023-08-23

Lead Sponsor: Celgene

Target Recruit Count: 13

Registration Number: NCT04196491

Locations: 🇺🇸
Local Institution - 117, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 108, Atlanta, Georgia, United States
🇺🇸
Local Institution - 110, Los Angeles, California, United States

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy